The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
1
Edited News | OCHA , UNHCR , WHO
The past two months of intensifying Israeli bombardment in Lebanon have been the “deadliest and most devastating” in decades as communities uprooted from the front line have continued to flee across the border to Syria, UN humanitarians said on Friday.
2
1
3
Edited News | UNOG
“State of Silence”: Diego Luna brings the fight to protect the press to the UN in Geneva
Mexican actor, producer and director Diego Luna has brought his fight to protect journalists all the way to the United Nations, in Geneva. Together with documentary director Santiago Masa, he is putting a spotlight on the silencing of investigative journalism in his country, and on the incredibly high price that many journalist have to pay in pursuit of truth.
1
1
1
Edited News | OHCHR , UNOG
“Today marks the grim milestone of 1,000 days since the Russian Federation launched its full-scale armed attack on Ukraine. Our Office has verified that at least 12,162 civilians have been killed since 24 February 2022, among them 659 children. At least another 26,919 civilians have been injured,” UN Human Rights spokesperson Jeremy Laurance told the bi-weekly press briefing in Geneva.
1
1
1
Edited News | OHCHR , UNOG
With COP29 in Baku now in its second - and final - week, UN Human Rights Chief Volker Türk has reiterated his call for urgent human rights-based climate action.
1
1
1
Edited News | UNIFIL , UNICEF , WHO
Lebanon: Increased violence along Blue Line and ‘horrific new normal’ for children
In southern Lebanon, peacekeepers have witnessed “shocking” destruction of villages along the Blue Line and ever-deeper Israeli ground incursions, while the situation of children across the country is becoming increasingly desperate, the UN said on Tuesday.
2
1
2
Press Conferences , Edited News | UNRWA
The head of the UN agency for Palestine refugees, UNRWA, confirmed on Monday that a large convoy of humanitarian aid was looted inside Gaza at the weekend, amid a near-total a breakdown in law and order and harassment of the agency’s staff by Israeli soldiers.
1
1
1
Edited News | OCHA
In the nearly 1,000 days since Russia’s full-scale invasion of Ukraine, thousands of civilians have been killed, the country’s energy infrastructure is on the brink and drones terrify communities on the front line, the UN’s top aid official in the country said on Friday.
2
1
2
Press Conferences , Edited News | OHCHR
Mexican actor, producer and director Diego Luna took a break from the big screen on Thursday to highlight the dangers faced by journalists in his country and beyond, condemning murders of reporters everywhere as “a scandal”.
1
1
1
Edited News | UNRWA
Gaza: ‘People are losing hope’ as aid access is refused to north, warns UNRWA
Besieged northern Gaza is a place of dead bodies lying in the streets and hospitals running out of blood packs – a situation that’s “nothing short of catastrophic”, the UN agency for Palestinian refugees (UNRWA) said on Tuesday.
1
1
1
Edited News | OHCHR
UN Human Rights Spokesperson Jeremy Laurence & Ajith Sunghay, Head of UN Human Rights Office in the Occupied Palestinian Territory, on Gaza
1
1
1
Edited News | UNHCR
Sudan’s displaced have endured “unimaginable suffering” in their search for shelter from the country’s ongoing war, UN humanitarians warned on Friday.
1
1
1
Edited News | WHO
‘Exceptional achievement’: Humanitarians reach over 105,000 with polio vaccine in north Gaza
Despite ongoing attacks and access challenges, humanitarians have managed to inoculate over 105,000 children in north Gaza with the second and final dose of the oral polio vaccine, the UN World Health Organization (WHO) said on Tuesday.